GSK is a science-led global healthcare company with a special purpose – to help people do more, feel better, live longer. Being headquartered in the UK GSK operates in more than 150 countries and has 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Around 100 000 employees work for GSK around the world with more than 16,000 people working in R&D.
More than 100 GSK prescription drugs are registered in Russia, which are used for the treatment of respiratory diseases, infectious diseases, including HIV infection, diseases of the central nervous system, as well as in the field of urology, immunology, rheumatology, dermatology and in vaccine procurement. GSK is one of the industry leaders in terms of investment in R&D in Russia.
Sean Reilly joined GSK Pharma Russia as VP & General Manager on August 1, 2020. Sean reports to Luis Arosemena, SVP Emerging Markets Global Pharma Executive, and leads Russia`s RLT team.
In his role, Sean is responsible for leading Russia's growth agenda across CEP, Respiratory, HIV, Vaccines, and Oncology. He will continue working on "Firebird", Russia accelerated development program, which aims to triple GSK business growth in Russia.
Sean was born in Ireland.
At 22 he moved to Colombia and began working in the pharmaceutical industry as a Medical representative. Later Sean held various positions in sales and marketing. Having worked for GSK for 24 years, Sean has strong experience and expertise in pharmaceutical industry. 14 years ago he was appointed to the position of General Manager GSK Colombia.
Before moving to Moscow, Sean held position of General director GSK Mexico.
Sean is married with two children.
Sanofi is a leading global healthcare company whose mission is to support people with health challenges. Over 100,000 Sanofi employees in more than 100 countries all over the world take action daily transforming scientific innovations into healthcare solutions.
Sanofi has been present in Russia since the 1970-ies being a leader of a Russian pharmaceutical market for the last 6 years2 and offering our patients a broad portfolio of original medicines and OTC drugs in key therapeutic areas (diabetes, cardiovascular disorders, oncology, rare diseases and multiple sclerosis, immunology), as well as vaccines.
Strategy of Sanofi in Russia corresponds with main healthcare priorities of the state: localization of products for treatment of socially significant diseases not only increased accessibility of innovative therapy for Russian patients, but also reinforced export potential of Russia in European Union.
General Manager Sanofi Eurasia from October 1, 2018. Prior to that since January 1, 2016 worked as General Manager, Rx, Sanofi Russia & Belarus.
Engineer by training with MBA degree from Cranfield School of Management, UK, Oxana has got more than twenty years of in-depth knowledge and experience in pharmaceutical industry with a number of leadership roles in Marketing, Strategic Planning, and Sales in Russia and UK.
Oxana started her career in pharmaceutical industry in 2001 with Eli Lilly UK. Over the following 13 years, she took on a number of senior management positions with increasing responsibility. In 2014, Oxana joined Sanofi as a Head of Diabetes BU in Russia.
Amgen is a biotechnology company engaged in the development, production and distribution of innovative drugs created by genetic engineering. Founded in 1980, Amgen Is a leader in the biotechnology industry and one of the first companies to unlock the potential of a new generation of effective and safe drugs and fundamentally new approaches to the treatment of serious diseases.
Amgen drugs have changed everyday medical practice, helping millions of people around the world to deal with severe oncological, hematological and nephrological diseases, rheumatoid arthritis and other serious pathologies. The extensive portfolio of drugs being developed to date (more than 50 new molecules at different stages of development and research) confirms the company's commitment to using scientific advances to improve people's lives.
Like 35 years ago, Amgen remains true to its mission:
"Serve patients suffering from severe diseases by developing innovative medicines to meet medical needs."
Mr. Gunaydin joined Amgen Russia in 2019. He has a wide international experience in pharma industry with varying responsibilities in countries like Turkey, Middle East & United States and in different roles in Finance, Strategy and Sales & Marketing areas.
Mr. Gunaydin holds an MA in Economics from the Bosphorus University, Istanbul.
The Association of Pharmaceutical Manufacturers of the Eurasian Economic Union was registered in 2012.
The purpose of the Association is to create conditions for the pharmaceutical market development in the Russian Federation and other EAEU countries, along with strengthening the position and competitiveness of the domestic pharmaceutical industry.
Members of the Association have main resource centres, including R&D laboratories and production facilities, located in the Russian Federation and other EAEU countries, as well as their own know-how and other intellectual property in the field of development and production of medicines and medical technologies. Among the members of the Association are leading full-cycle pharmaceutical companies, such as “Active Component” JSC, “Biocad” CJSC, “Generium” JSC, OOO “GEROPHARM”, “Nanolek” LLC, “NPO Petrovax Pharm” LLC, “Polysan” LTD, “Pharmstandard” JSC, and HTC “ChemRar”
Educational background: Department of Philosophy of the Ural State University with major in political science. Cand. Sc. Philosophy. Executive МВА, Moscow School of Management SKOLKOVO.
Since 2019: Director General of the Eurasian Centre for Integration Research and Communications. From 2015 to 2019: Government Relations Director at X5 Retail Group. Previous public service positions: Assistant to the Head of the Federal Tax Service of Russia, Assistant to the Deputy Prime Minister of Russia, Director of the Department of Economic Analysis and Prospective Planning of the Ministry of Industry and Trade of Russia, Deputy Minister of Industry and Trade of Russia.
Bristol Myers Squibb is the company of breakthroughs – the kind that transform patients` lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we`ll never give up our search for more hope, for more people, around the world.
We focus on innovations, as we believe in the power of science to address some of the most challenging diseases of our time. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and HCV. We pioneered a class of medicines that harnesses the power of the immune system to treat cancer.
Generating new ideas and thinking differently are at the heart of everything we do for patients. We are driven by the knowledge that our efforts can make the difference for a patient.
Alisa Dzhangiryants has been working in the pharmaceutical market for over 18 years. She joined Bristol-Myers Squibb in 2012 as a Project Manager for Immunology & Oncology. In 2014, she moved to the position of the Head of the group of Regional Market Access Managers.
Since 2017, he has been the Director of Market Access and Pricing Department.
Alisa graduated from the First Moscow State Medical University named after I. M. Sechenov with a PhD in Pharmaceutical Sciences.
Teva Around the World
Teva Pharmaceutical Industries Ltd. is one of the world’s pharmaceutical leaders. Headquartered in Israel, Teva delivers high-quality solutions used by approximately 200 million patients who need treatment in 60 markets every day.
Teva is a global leading generic medicines producer, with a portfolio of over 1,800 molecules that help to produce a wide range of generic products for almost every kind of treatment.
Teva in Russia
Opening opportunities for affordable health – that’s Teva’s purpose. Over 25 years Teva has been opening up opportunities that afford people access to quality medicines, advanced solutions and the information they need to manage their health. Teva began operating in Russia in 1995 and today it is one of the largest pharmaceutical companies in the Russian market with a portfolio of over 300 products.
Erick Roche is a seasoned strategic professional with over 27 years experience in the pharmaceutical industry and a successful track record in the pharmaceutical companies in North America and Europe. Today he leads a team of more than 1,800 people in Russia, Eurasia, Turkey and MEA.
Prior to his appointment as the Head of Cluster in July 2018 Erick Roche spent almost 7 years as General Manager of Teva Laboratories France.
Before joining Teva Laboratories, Erick Roche worked as General Director of a Biogaran. Before his 15 years at Biogaran he was responsible for Business Development at Apotex Inc.
From 2014 to 2018 Erick Roche was the President of GEMME, the French Generics Trade Association; a member of the European Generics Association (MFE) and a board member of the French Pharma Trade Association (LEEM).
Irina has worked for AstraZeneca since 2009. Before coming to Russia, Irina held the position of General Manager at AstraZeneca Ukraine.
Prior to joining AstraZeneca, Irina held regional roles at GSK Pharma headquarters in London, UK.
Irina has work experience in marketing, management and human resources development.
She has degrees from Newcastle University and South Bank University; she also has an MBA from INSEAD Business School.
Since February 2018, Irina has been a member of the General Council of the All-Russia Public Organization “Business Russia” and since December 2019 – a member of the Coordination Council.
Petrovax is a Russian full-cycle biopharmaceutical company with 25 years of successful experience. It was founded in 1996 by a group of Russian scientists. Since 2014, the company has been a part of the Interros Group.
The product portfolio includes original pharmaceutical products and vaccines, generics and dietary supplements. The company has its own research center and investment program for R&D, and holds more than 20 new molecule and manufacturing process patents. The company's complex for manufacturing of APIs and finished dosage forms is located in the Moscow region and operates in full compliance with the Russian and international GMP standards. Petrovax has over 700 employees.
Petrovax's partners are the world's leading pharmaceutical companies: Pfizer, Abbott, Boehringer Ingelheim, CanSino Biologics Inc. Petrovax is the largest Russian exporter of original medicinal products. The company exports products to the countries of the EAEU, the Middle East and the EU.
In 2020-2021 Petrovax conducted large-scale trials of coronavirus vaccine and original medicines products against COVID-19 in Russia and the EU.
Before joining Petrovax in 2018, Mikhail Tsyferov gained extensive experience in a number of large investment companies.
From 2018 to present – President of NPO Petrovax Pharm LLC (part of the Interros Group), Member of the Board of Directors.
From 2016 to present – Managing Director of the Winter Capital Fund.
From 2008 to 2016 – manager of the investment department of Interros.
From 2007 to 2008 – employee of the capital markets department at Renaissance Capital.
Acted as an investor in more than 20 Private equity / VC transactions.
He graduated from the School of International Economic Relations of MGIMO (Moscow State Institute of International Relations) in 2007.